Exploring the Relationship Between North Star Ambulatory Assessment and Health Utilities Index Scores in Duchenne Muscular Dystrophy

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2023 Jul 19

PMID 37468890

Authors

Ivana Audhya

Basia Rogula

Shelagh M Szabo

David Feeny

Talshyn Bolatova

Katherine Gooch

Affiliations

Soon will be listed here.

Abstract

Background: The North Star Ambulatory Assessment (NSAA) documents motor performance in ambulatory individuals with Duchenne muscular dystrophy (DMD). Health Utilities Index (HUI) scores, reflecting preferences for health-related quality-of-life (HRQoL) implications of health states, are commonly estimated within trials. This study sought to characterize the relationship between the NSAA score and utility in DMD.

Methods: Family members serving as proxy respondents for placebo-treated ambulatory individuals with DMD (NCT01254019; BioMarin Pharmaceuticals Inc) completed the HUI and the NSAA (score range, 0-34). Mean change over time on these measures was estimated, and the correlation between changes in NSAA score and a) HUI utility; b) HUI3 ambulation and HUI2 mobility attribute scores, over 48 weeks was calculated.

Results: Baseline mean (range) age was 8.0 years (5-16; n = 61) and mean (standard deviation [SD]) scores were 0.87 (0.13; HUI2), 0.82 (0.19; HUI3), and 21.0 (8.1; NSAA). Mean (SD) change over 48 weeks was -0.05 (0.14; HUI2), -0.06 (0.19; HUI3), and -2.9 (4.7; NSAA). Weak positive correlations were observed between baseline NSAA score and HUI utility (HUI2: r = 0.29; HUI3: r = 0.17) and for change over 48 weeks (HUI2: r = 0.16; HUI3: r = 0.15). Stronger correlations were observed between change in NSAA score and the HUI3 ambulation (r = 0.41) and HUI2 mobility (r = 0.41) attributes.

Conclusions: Among ambulatory individuals with DMD, NSAA score is weakly correlated with HUI utility, suggesting that motor performance alone does not fully explain HRQoL. Stronger relationships were observed between HUI ambulation and mobility attributes, and NSAA. Although unidimensional measures like the NSAA are informative for documenting disease-specific health impacts, they may not correlate well with measures of overall health status; requiring use in conjunction with other patient-reported and preference-based outcomes.

Citing Articles

Height development and multiple bone health indicators in children aged 2-12 years with Duchenne muscular dystrophy (DMD).

Wang B, Zhou L, Li S, Xu H, Guo Y, Hu Q PLoS One. 2025; 20(1):e0316938.

PMID: 39792921 PMC: 11723629. DOI: 10.1371/journal.pone.0316938.

Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.

Rabbia M, Ormazabal M, Staunton H, Veenstra K, Eggenspieler D, Annoussamy M J Neuromuscul Dis. 2024; 11(3):701-714.

PMID: 38640165 PMC: 11091611. DOI: 10.3233/JND-230188.

References

Yiu E, Kornberg A . Duchenne muscular dystrophy. J Paediatr Child Health. 2015; 51(8):759-64. DOI: 10.1111/jpc.12868. View

Szabo S, Audhya I, Rogula B, Feeny D, Gooch K . Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI). Health Qual Life Outcomes. 2022; 20(1):93. PMC: 9188127. DOI: 10.1186/s12955-022-02001-0. View

Haberkamp M, Moseley J, Athanasiou D, de Andres-Trelles F, Elferink A, Rosa M . European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscul Disord. 2019; 29(7):514-516. DOI: 10.1016/j.nmd.2019.06.003. View

Szabo S, Salhany R, Deighton A, Harwood M, Mah J, Gooch K . The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis. 2021; 16(1):237. PMC: 8141220. DOI: 10.1186/s13023-021-01862-w. View

Muntoni F, Domingos J, Manzur A, Mayhew A, Guglieri M, Sajeev G . Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS One. 2019; 14(9):e0221097. PMC: 6719875. DOI: 10.1371/journal.pone.0221097. View

Pane M, Mazzone E, Sivo S, Sormani M, Messina S, DAmico A . Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One. 2014; 9(10):e108205. PMC: 4182715. DOI: 10.1371/journal.pone.0108205. View

Uttley L, Carlton J, Woods H, Brazier J . A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. Health Qual Life Outcomes. 2018; 16(1):237. PMC: 6299926. DOI: 10.1186/s12955-018-1062-0. View

Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J . Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int. 2011; 17(2):101-9. DOI: 10.1002/pri.520. View

Landfeldt E, Lindgren P, Bell C, Guglieri M, Straub V, Lochmuller H . Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol. 2015; 58(5):508-15. PMC: 4949722. DOI: 10.1111/dmcn.12938. View

10.

Wolowacz S, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R . Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value Health. 2016; 19(6):704-719. DOI: 10.1016/j.jval.2016.06.001. View

11.

Mazzone E, Martinelli D, Berardinelli A, Messina S, DAmico A, Vasco G . North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010; 20(11):712-6. DOI: 10.1016/j.nmd.2010.06.014. View

12.

Connolly A, Florence J, Cradock M, Malkus E, Schierbecker J, Siener C . Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord. 2013; 23(7):529-39. PMC: 3743677. DOI: 10.1016/j.nmd.2013.04.005. View

13.

Szabo S, Audhya I, Malone D, Feeny D, Gooch K . Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review. Qual Life Res. 2019; 29(3):593-605. PMC: 7028804. DOI: 10.1007/s11136-019-02355-x. View

14.

Mirski K, Crawford T . Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosis. J Pediatr. 2014; 165(5):1008-10. DOI: 10.1016/j.jpeds.2014.07.006. View

15.

Wein N, Alfano L, Flanigan K . Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin North Am. 2015; 62(3):723-42. DOI: 10.1016/j.pcl.2015.03.008. View

16.

Connolly A, Florence J, Cradock M, Eagle M, Flanigan K, McDonald C . One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol. 2014; 50(6):557-63. PMC: 4197452. DOI: 10.1016/j.pediatrneurol.2014.02.006. View

17.

Mazzone E, Messina S, Vasco G, Main M, Eagle M, DAmico A . Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009; 19(7):458-61. DOI: 10.1016/j.nmd.2009.06.368. View

18.

Modaresi M, Roshanzamir Z, Shirzadi R . The Correlation of Health-Related Quality of Life with Cystic Fibrosis Severity Markers in Chest CT Scan and 6-Minute Walk Test: A Cross-Sectional Study. Indian J Pediatr. 2021; 89(2):113-117. DOI: 10.1007/s12098-021-03784-8. View

19.

Wang R, Barthelemy F, Martin A, Douine E, Eskin A, Lucas A . DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Hum Mutat. 2018; 39(9):1193-1202. PMC: 6175390. DOI: 10.1002/humu.23561. View

20.

Lans C, Cider A, Nylander E, Brudin L . The relationship between six-minute walked distance and health-related quality of life in patients with chronic heart failure. Scand Cardiovasc J. 2022; 56(1):310-315. DOI: 10.1080/14017431.2022.2107234. View